Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Physiological Reviews

• Publication date

  2015-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/physrev.00013.2014PMID 25834231
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification and Characterization of GLP-1 Receptor–Expressing Cells Using a New Transgenic Mouse Model

  2014cited by this paper
• GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.

  2014cited by this paper
• Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.

  2014cited by this paper
• Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency.

  2014cited by this paper
• Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia.

  2014cited by this paper
• Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose

  2014cited by this paper
• The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs.

  2014cited by this paper
• GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6–Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering

  2014cited by this paper
• Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus

  2014cited by this paper
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

  2014cited by this paper
• Pancreatic α-cell hyperplasia: facts and myths.

  2014cited by this paper
• Contribution of Endogenous Glucagon-Like Peptide 1 to Glucose Metabolism After Roux-en-Y Gastric Bypass

  2014cited by this paper
• Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy.

  2014cited by this paper
• Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones.

  2013cited by this paper
• Pharmacology, physiology, and mechanisms of incretin hormone action.

  2013cited by this paper
• High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.

  2013cited by this paper
• Paracrine and autocrine interactions in the human islet: more than meets the eye.

  2013cited by this paper
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

  2013cited by this paper
• Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

  2013cited by this paper
• Small human islets comprised of more β-cells with higher insulin content than large islets

  2013cited by this paper
• Identification and characterisation of glucagon-like peptide-1 receptor expressing cells using a new transgenic mouse model

  2013cited by this paper
• Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes

  2013cited by this paper
• Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls

  2013cited by this paper
• Preproglucagon (PPG) neurons innervate neurochemically identified autonomic neurons in the mouse brainstem.

  2013cited by this paper
• Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

  2013cited by this paper
• Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux‐en‐Y gastric bypass

  2013cited by this paper
• GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.

  2013cited by this paper
• Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.

  2013influential reference
• Liver-Specific Disruption of the Murine Glucagon Receptor Produces α-Cell Hyperplasia

  2013cited by this paper
• Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism.

  2013cited by this paper
• Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

  2013cited by this paper
• Improved glycemic control enhances the incretin effect in patients with type 2 diabetes.

  2013cited by this paper
• Glucose metabolism is altered after loss of L cells and α-cells but not influenced by loss of K cells.

  2013cited by this paper
• Vertical Sleeve Gastrectomy Is Effective in Two Genetic Mouse Models of Glucagon-Like Peptide 1 Receptor Deficiency

  2013cited by this paper
• Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity.

  2013cited by this paper
• Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials

  2013cited by this paper
• Long-Term Effects of Bariatric Surgery on Meal Disposal and β-Cell Function in Diabetic and Nondiabetic Patients

  2013influential reference
• In Situ Electrophysiological Examination of Pancreatic α Cells in the Streptozotocin-Induced Diabetes Model, Revealing the Cellular Basis of Glucagon Hypersecretion

  2013cited by this paper
• Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver.

  2013cited by this paper
• Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

  2013cited by this paper
• Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

  2013cited by this paper
• GLP-1 Action and Glucose Tolerance in Subjects With Remission of Type 2 Diabetes After Gastric Bypass Surgery

  2013cited by this paper
• Tolbutamide Controls Glucagon Release From Mouse Islets Differently Than Glucose

  2013cited by this paper
• Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt.

  2013cited by this paper
• Ectopic Expression of GIP in Pancreatic β-Cells Maintains Enhanced Insulin Secretion in Mice With Complete Absence of Proglucagon-Derived Peptides

  2013cited by this paper
• Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.

  2012cited by this paper
• Direct effect of GLP-1 infusion on endogenous glucose production in humans

  2012cited by this paper
• The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.

  2012cited by this paper
• Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia.

  2012cited by this paper
• Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice

  2012cited by this paper
• Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human

  2012cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012cited by this paper
• Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.

  2012cited by this paper
• A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets

  2012cited by this paper
• Heterozygous Mutations Causing Partial Prohormone Convertase 1 Deficiency Contribute to Human Obesity

  2012cited by this paper
• A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents

  2012cited by this paper
• Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists

  2012cited by this paper
• Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

  2012cited by this paper
• GLP-1 Response to a Mixed Meal: What Happens 10 Years after Roux-en-Y Gastric Bypass (RYGB)?

  2012cited by this paper
• Transformation of postingestive glucose responses after deletion of sweet taste receptor subunits or gastric bypass surgery.

  2012cited by this paper
• The Anorectic Effect of GLP-1 in Rats Is Nutrient Dependent

  2012cited by this paper
• The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes

  2012cited by this paper
• Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP

  2012cited by this paper
• Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

  2012cited by this paper
• Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

  2012cited by this paper
• Alterations in energy balance following exenatide administration.

  2012cited by this paper
• Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes

  2012cited by this paper
• Metabolic/bariatric surgery

  2012cited by this paper
• Regulation of calcium in pancreatic α- and β-cells in health and disease

  2012cited by this paper
• The role of the Wnt signaling pathway in incretin hormone production and function

  2012cited by this paper
• Formation of a human β-cell population within pancreatic islets is set early in life.

  2012cited by this paper
• Bariatric surgery versus intensive medical therapy in obese patients with diabetes.

  2012cited by this paper
• Vagal Afferents Mediate Early Satiation and Prevent Flavour Avoidance Learning in Response to Intraperitoneally Infused Exendin‐4

  2012cited by this paper
• Adaptive reciprocity of lipid and glucose metabolism in human short-term starvation.

  2012cited by this paper
• Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects

  2012cited by this paper
• Regulation of GIP and GLP1 Receptor Cell Surface Expression by N-Glycosylation and Receptor Heteromerization

  2012cited by this paper
• The human microbiome: at the interface of health and disease

  2012cited by this paper
• Molecular mechanisms underlying bile acid‐stimulated glucagon‐like peptide‐1 secretion

  2012cited by this paper
• Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.

  2012cited by this paper
• Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents

  2012cited by this paper
• GLP-1 and energy balance: an integrated model of short-term and long-term control

  2011cited by this paper
• Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors.

  2011cited by this paper
• CCK Stimulation of GLP-1 Neurons Involves α1-Adrenoceptor–Mediated Increase in Glutamatergic Synaptic Inputs

  2011cited by this paper
• A Whole-Body Model for Glycogen Regulation Reveals a Critical Role for Substrate Cycling in Maintaining Blood Glucose Homeostasis

  2011cited by this paper
• The potential role of glucagon‐like peptide‐1 or its analogues in enhancing glycaemic control in critically ill adult patients

  2011cited by this paper
• How neural mediation of anticipatory and compensatory insulin release helps us tolerate food.

  2011cited by this paper
• Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis

  2011cited by this paper
• Physiologic action of glucagon on liver glucose metabolism

  2011cited by this paper
• Metabolic impact of glucagon deficiency

  2011cited by this paper
• The role of dysregulated glucagon secretion in type 2 diabetes

  2011cited by this paper
• Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice.

  2011cited by this paper
• Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in Humans

  2011cited by this paper
• 11β‐Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus

  2011cited by this paper
• Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.

  2011influential reference
• Hyperphagia and Increased Fat Accumulation in Two Models of Chronic CNS Glucagon-Like Peptide-1 Loss of Function

  2011influential reference
• Brain glucose sensing and neural regulation of insulin and glucagon secretion

  2011cited by this paper
• Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency.

  2011cited by this paper
• Glucagon gene expression in the endocrine pancreas: the role of the transcription factor Pax6 in α‐cell differentiation, glucagon biosynthesis and secretion

  2011cited by this paper
• Preproglucagon neurons project widely to autonomic control areas in the mouse brain.

  2011cited by this paper
• The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.

  2011cited by this paper

• Degradation Products of Guangdong Finger Citron Water-Soluble Polysaccharides by Gut Microbiota Ameliorate Type 2 Diabetes Mellitus via the Cyclic Adenosine Monophosphate Pathway.

  2026cites this paper
• Modulatory Effects of Artocarpus altilis Leaf Extract on Metabolic and Inflammatory Markers in Obesity

  2026cites this paper
• Cardiometabolic Surgery for Treatment of Hypertension

  2026cites this paper
• Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2

  2026cites this paper
• Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors

  2026cites this paper
• The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications

  2026cites this paper
• Prise en charge clinique et thérapeutique des hépatopathies stéatosiques associées à une dysfonction métabolique (MASLD)

  2026cites this paper
• Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review

  2026influential citation
• SEL1L-HRD1 ER-associated degradation facilitates prohormone convertase 2 maturation and glucagon production in islet α cells.

  2026cites this paper
• Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.

  2026cites this paper
• Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives

  2025cites this paper
• GLP-1R in diabetes mellitus: from basic discovery to therapeutics development

  2025cites this paper
• 1,25-D3 Protects Diabetic Brain Injury Through GLP-1R/PI3K/Akt Pathway by Experimental and Molecular Docking Studies

  2025cites this paper
• Peptides are cardioprotective drugs of the future. Glucagon-like peptide-1

  2025cites this paper
• Study on gene expression in stomach at different developmental stages of human embryos

  2025cites this paper
• Integrated meta-analysis and network pharmacology analysis: evaluation of Zhigancao decoction as treatment for diabetic cardiomyopathy

  2025cites this paper
• Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders

  2025cites this paper
• Neurite outgrowth inhibitor-B (Nogo-B) in physiology and disease.

  2025cites this paper
• Future Perspective on Glucagon-like Peptide-1/2 as Potential Biomarkers of Acute Intestinal Ischemia.

  2025cites this paper
• Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice

  2025cites this paper
• Glucokinase: evolution, regulatory properties, role in the pathogenesis of type 2 diabetes mellitus

  2025cites this paper
• Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development.

  2025cites this paper
• Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review.

  2025cites this paper
• Dietary fiber derived short-chain fatty acids as a critical driver of the gut–bone axis in animal bone health: A review

  2025cites this paper
• Blood-brain barrier integrity and transport of major hormones are unchanged in mice with euglycemic hyperinsulinemia.

  2025cites this paper
• New Biomarkers of Acute Intestinal Ischemia: A Prospective Study Validating the Interest of GLP-1 and GLP-2.

  2025cites this paper
• Immunolocalization and immunoexpression levels of sibling peptides nesfatin-1 and ghrelin, and their potentially shared receptor in the gastrointestinal tract of Holstein-Friesian bulls.

  2025cites this paper
• Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide

  2025cites this paper
• Western Diet Induces Changes in Gene Expression in Multiple Tissues During Early Insulin Resistance and Glucose Intolerance in Male C57BL/6 Mice

  2025cites this paper
• Integrated transcriptomic and metabolomic analysis reveals key regulatory genes and pathways associated with feed conversion efficiency in Tianchang Sanhuang chicken

  2025cites this paper
• Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence

  2025cites this paper
• Characterizing Duodenal Immune Microenvironment in Functional Dyspepsia: An AutoML-Driven Diagnostic Framework

  2025cites this paper
• Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review

  2025cites this paper
• Advances in Oral Biomacromolecule Therapies for Metabolic Diseases

  2025cites this paper
• Paeoniflorin: a review of its pharmacology, pharmacokinetics and toxicity in diabetes

  2025cites this paper
• G-Protein-Coupled Receptor (GPCR) Signaling and Pharmacology in Metabolism: Physiology, Mechanisms, and Therapeutic Potential

  2025cites this paper
• Role of GLP-1 receptor agonists in sepsis and their therapeutic potential in sepsis-induced muscle atrophy (Review)

  2025cites this paper
• SEL1L-HRD1 ER-Associated Degradation Facilitates Prohormone Convertase 2 Maturation and Glucagon Production in Islet α Cells

  2025cites this paper
• Understanding peptide hormones: from precursor proteins to bioactive molecules.

  2025cites this paper
• Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice

  2025influential citation
• A microbial amino-acid-conjugated bile acid, tryptophan-cholic acid, improves glucose homeostasis via the orphan receptor MRGPRE.

  2025cites this paper
• Beneficial Effects of Carbohydrate Restriction in Type 2 Diabetes Can Be Traced to Changes in Hepatic Metabolism.

  2025cites this paper
• The central signaling pathways related to metabolism-regulating hormones of the gut-brain axis: a review

  2025cites this paper
• GLP1 secretagogue cinnamaldehyde upregulates GLP1/PI3K/AKT and Nrf2 pathways to exert neuroprotection in a rotenone induced mouse model of Parkinson's disease.

  2025cites this paper
• Impact of a structured food sequence and mobile health monitoring on gestational diabetes outcomes: a clinical trial

  2025cites this paper
• Proglucagon-derived Peptides: Human Physiology and Therapeutic Potential.

  2025cites this paper
• Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions.

  2025cites this paper
• Lacticaseibacillus paracasei Glu-07: A Promising Probiotic Candidate for the Management of Type 2 Diabetes Mellitus

  2025cites this paper
• The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition

  2025cites this paper
• Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

  2025cites this paper
• GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects

  2025cites this paper
• Oral Treatment of Obesity by GLP-1 and Its Analogs

  2025cites this paper
• Obesity and Hypertension: Etiology and the Effects of Diet, Bariatric Surgery, and Antiobesity Drugs.

  2025cites this paper
• Peptides are cardioprotective drugs of the future. Adrenomedullin

  2025cites this paper
• The gut microbiota-derived metabolites regulate bone extracellular matrix homeostasis: Mechanisms and therapeutic implications.

  2025cites this paper
• GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance.

  2025cites this paper
• Using glucagon receptor antagonism to evaluate the physiological effects of extrapancreatic glucagon in totally pancreatectomised individuals: a randomised controlled trial

  2025cites this paper
• GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy

  2025cites this paper
• Quantification of glucagon and oxyntomodulin by protein precipitation-immunoaffinity enrichment-LC-MS/MS

  2025cites this paper
• Multiscale Synergy Networks Offer Insights into Disease and Comorbidity Mechanisms.

  2025cites this paper
• Extracellular Vesicle‐Like Nanoparticles Present in Fermented Botanical Products Suppress Fat Absorption in the Gut

  2025cites this paper
• Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions

  2025cites this paper
• Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence

  2025cites this paper
• Effects of Varying Ratios of Hawthorn Fruit Extract on Nesfatin-1, Glp-1 and ctni Response in Streptozotocin-induced Diabetic Rats

  2025cites this paper
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Diabetes and Obesity: Implications for Periodontology and Family Dentistry

  2025cites this paper
• Bacteroides acidifaciens alleviates high-fat diet-induced obesity-related osteoporosis by regulating gut microbiota and bile acid metabolism via the gut-bone axis.

  2025cites this paper
• Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials

  2025cites this paper
• Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy

  2025cites this paper
• Microbiota metabolites in bone: Shaping health and Confronting disease

  2024cites this paper
• Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.

  2024cites this paper
• An organism-wide atlas of hormonal signaling based on the mouse lemur single-cell transcriptome

  2024cites this paper
• Thermogenic adipose tissues: promising therapeutic targets for metabolic diseases: Thermogenic fats and obesity.

  2024cites this paper
• Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists

  2024influential citation
• Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?

  2024cites this paper
• Risk factors for irritable bowel syndrome: A review

  2024cites this paper
• Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion

  2024cites this paper
• Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

  2024cites this paper
• The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.

  2024cites this paper
• Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures

  2024cites this paper
• Tyrosine nitration of glucagon impairs its function: Extending the role of heme in T2D pathogenesis.

  2024cites this paper
• Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.

  2024cites this paper
• TRPV4 couples with NCX1 to mediate glucose‐dependent glucagon‐like peptide‐1 release and improve glucose homeostasis

  2024cites this paper
• Diet and physical exercise as key players to tackle MASLD through improvement of insulin resistance and metabolic flexibility

  2024cites this paper
• Modeling sex-specific whole-body metabolic responses to feeding and fasting

  2024cites this paper
• Ameliorative effect of yam bean (Pachyrhizus erosus L.) fiber on glucagon-like peptide 1 expression, oxidative stress and histopathology of the small ıntestine in mice fed high-fat diet

  2024cites this paper
• The role of PANDER and its interplay with IL-6 in the regulation of GLP-1 secretion

  2024cites this paper
• The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity

  2024cites this paper
• Gut Microbiota−Tryptophan Metabolism−GLP-1 Axis Participates in β-Cell Regeneration Induced by Dapagliflozin

  2024cites this paper
• GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences

  2024cites this paper
• Serotonin signaling to regulate energy metabolism: a gut microbiota perspective

  2024cites this paper
• Potential applications of engineered bacteria in disease diagnosis and treatment

  2024cites this paper
• The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.

  2024cites this paper
• Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance

  2024cites this paper
• Impact of coffee and its bioactive compounds on the risks of type 2 diabetes and its complications: A comprehensive review.

  2024cites this paper
• Intestinal Nogo-B reduces GLP1 levels by binding to proglucagon on the endoplasmic reticulum to inhibit PCSK1 cleavage

  2024cites this paper
• Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature

  2024cites this paper
• Genetic evidence for repurposing of glucagon-like peptide-1 receptor agonists to prevent chronic liver diseases

  2024cites this paper
• Revisiting the evolution of family B1 GPCRs and ligands: Insights from mollusca.

  2024cites this paper
• Receptors and Signaling Pathways Controlling Beta-Cell Function and Survival as Targets for Anti-Diabetic Therapeutic Strategies

  2024cites this paper